Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

 

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
A

bsAb and IO for R/R MM in 2021: Are Teclistamab, Talquetamab, & Cevostamab Showing Promising Activity?

By Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient FEATURING Adam D. Cohen
By Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient FEATURING Adam D. Cohen
0 views
March 2, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon
Controversies and Update for Patient Care in Multiple Myeloma
17:23
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

UPenn Expert Analysis 40 y/o Patient With MM: How to Treat Systemica…

Feat. E. Stadtmauer, D. Vogl, A. Cohen, S. Wallace
10:17
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

UPenn Physicians Analyze a Challenging Case of MM: What Systemic The…

Feat. E. Stadtmauer, D. Vogl, A. Cohen, S. Wallace
15:36
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

CAR-T and IO for R/R MM in 2021: Is bb2121 Safe and Does It Improve …

Feat. A. Cohen
15:36
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

bsAb and IO for R/R MM in 2021: Are Teclistamab, Talquetamab, & …

Feat. A. Cohen
22:31
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

2021 Experimental Therapies for Relapsed Myeloma: Antibodies (Dara, …

Feat. D. Vogl